Sequential Intravesical Mitomycin Plus Bacillus Calmette-Guérin for Non-muscle-invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2014 Nov 27

PMID 25424854

Citations 19

Authors

Robert S Svatek

Xiang Ru Zhao

Edwin E Morales

Mithilesh K Jha

Timothy Y Tseng

Cory M Hugen

Vincent Hurez

Javier Hernandez

Tyler J Curiel

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine the safety and toxicities of sequential MMC (mitomycin C) + BCG (bacillus Calmette-Guérin) in patients with non-muscle-invasive bladder cancer (NMIBC) and explore evidence for potentiation of BCG activity by MMC.

Experimental Design: A 3 + 3 phase I dose-escalation trial of six weekly treatments was conducted in patients with NMIBC. MMC (10, 20, or 40 mg) was instilled intravesically for 30 minutes, followed by a 10-minute washout with gentle saline irrigation and then instillation of BCG (half or full strength) for 2 hours. Urine cytokines were monitored and compared with levels in a control cohort receiving BCG only. Murine experiments were carried out as described previously.

Results: Twelve patients completed therapy, including 3 patients receiving full doses. The regimen was well tolerated with no treatment-related dose-limiting toxicities. Urinary frequency and urgency, and fatigue were common. Eleven (91.7%) patients were free of disease at a mean (range) follow-up of 21.4 (8.4-27.0) months. Median posttreatment urine concentrations of IL2, IL8, IL10, and TNFα increased over the 6-week treatment period. A greater increase in posttreatment urinary IL8 during the 6-week period was observed in patients receiving MMC + BCG compared with patients receiving BCG monotherapy. In mice, intravesical MMC + BCG skewed tumor-associated macrophages (TAM) toward a beneficial M1 phenotype.

Conclusions: Instillation of sequential MMC + BCG is safe tolerable up to 40-mg MMC plus full-strength BCG. This approach could provide improved antitumor activity over BCG monotherapy by augmenting beneficial M1 TAMs.

Citing Articles

Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine, and Docetaxel for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: Updated Systematic Review and Meta-Analysis.

Matloubieh J, Hanelin D, Agalliu I Cancers (Basel). 2025; 16(24.

PMID: 39766024 PMC: 11674742. DOI: 10.3390/cancers16244125.

Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.

Derre L, Lucca I, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias S J Immunother Cancer. 2023; 11(12).

PMID: 38101861 PMC: 10729085. DOI: 10.1136/jitc-2023-008020.

PcrV Enhances the Nitric Oxide-Mediated Tumoricidal Activity of Tumor-Associated Macrophages a TLR4/PI3K/AKT/mTOR-Glycolysis-Nitric Oxide Circuit.

Yu H, Bai Y, Qiu J, He X, Xiong J, Dai Q Front Oncol. 2021; 11:736882.

PMID: 34900687 PMC: 8654729. DOI: 10.3389/fonc.2021.736882.

CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.

Reyes R, Zhang C, Deng Y, Ji N, Mukherjee N, Padron A Oncoimmunology. 2021; 10(1):2006529.

PMID: 34858732 PMC: 8632314. DOI: 10.1080/2162402X.2021.2006529.

BCG immunotherapy inhibits cancer progression by promoting the M1 macrophage differentiation of THP‑1 cells via the Rb/E2F1 pathway in cervical carcinoma.

Liu L, Shi W, Xiao X, Wu X, Hu H, Yuan S Oncol Rep. 2021; 46(5).

PMID: 34581419 PMC: 8493057. DOI: 10.3892/or.2021.8196.

References

Saint F, Kurth N, Maille P, Vordos D, Hoznek A, Soyeux P . Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer. 2003; 107(3):434-40. DOI: 10.1002/ijc.11352. View

Kavoussi L, Brown E, Ritchey J, Ratliff T . Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest. 1990; 85(1):62-7. PMC: 296387. DOI: 10.1172/JCI114434. View

Vita F, Siracusano S, Abbate R, Ciciliato S, Borelli V, Soranzo M . BCG prophylaxis in bladder cancer produces activation of recruited neutrophils. Can J Urol. 2011; 18(1):5517-23. View

Clark P, Agarwal N, Biagioli M, Eisenberger M, Greenberg R, Herr H . Bladder cancer. J Natl Compr Canc Netw. 2013; 11(4):446-75. DOI: 10.6004/jnccn.2013.0059. View

Nowak A, Robinson B, Lake R . Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 2002; 62(8):2353-8. View

Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G . Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full.... Eur Urol. 2013; 65(1):69-76. DOI: 10.1016/j.eururo.2013.07.021. View

Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F . Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002; 20(15):3193-8. DOI: 10.1200/JCO.2002.02.066. View

Jinesh G G, Chunduru S, Kamat A . Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL. J Leukoc Biol. 2012; 92(1):233-44. PMC: 3382315. DOI: 10.1189/jlb.1211623. View

de Boer E, De Jong W, van der Meijden A, Steerenberg P, Witjes F, Vegt P . Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res. 1991; 19(1):45-50. DOI: 10.1007/BF00294021. View

10.

Bohle A, Gerdes J, Ulmer A, Hofstetter A, Flad H . Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol. 1990; 144(1):53-8. DOI: 10.1016/s0022-5347(17)39365-5. View

11.

Jackson A, Alexandroff A, Kelly R, Skibinska A, Esuvaranathan K, Prescott S . Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol. 1995; 99(3):369-75. PMC: 1534215. DOI: 10.1111/j.1365-2249.1995.tb05560.x. View

12.

de Reijke T, de Boer E, Kurth K, Schamhart D . Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol. 1996; 155(2):477-82. View

13.

Malmstrom P, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E . An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56(2):247-56. DOI: 10.1016/j.eururo.2009.04.038. View

14.

Rabinowitz R, Smith D, Tiemann D, Hudson M . Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients. J Urol. 1997; 158(5):1728-31; discussion 1731-2. DOI: 10.1016/s0022-5347(01)64111-9. View

15.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2007; 8(1):59-73. DOI: 10.1038/nri2216. View

16.

Biot C, Rentsch C, Gsponer J, Birkhauser F, Jusforgues-Saklani H, Lemaitre F . Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 2012; 4(137):137ra72. DOI: 10.1126/scitranslmed.3003586. View

17.

Luo Y, Yamada H, Evanoff D, Chen X . Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol. 2006; 146(1):181-8. PMC: 1809722. DOI: 10.1111/j.1365-2249.2006.03191.x. View

18.

Watanabe E, Matsuyama H, Matsuda K, Ohmi C, Tei Y, Yoshihiro S . Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother. 2003; 52(8):481-6. PMC: 11032925. DOI: 10.1007/s00262-003-0384-9. View

19.

Bingle L, Brown N, Lewis C . The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196(3):254-65. DOI: 10.1002/path.1027. View

20.

Mitsogiannis I, Psaroudaki Z, Perrea D, Paniara O, Melekos M, Zervas A . In vitro biocompatibility between mitomycin-C (MMC) and bacillus Calmette-Guerin (BCG). Anticancer Res. 2007; 26(6B):4569-73. View